Close Menu

NEW YORK – By analyzing circulating tumor DNA (ctDNA) samples after treatment, it may be possible to identify stage III colon cancer patients who are at increased risk of relapse and disease progression, new research suggests.

"Our study highlights the potential clinical utility of ctDNA to guide therapeutic decision-making," corresponding author Jeanne Tie, a medical oncologist and personalized oncology researcher specializing in colorectal cancer at the Walter and Eliza Hall Institute of Medical Research, and her colleagues wrote. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Dec
10
Sponsored by
Congenica II

This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.